David Kallend,
Vice President, Global Medical Director
Following graduation from Kings College Hospital School of Medicine in London, Dr David Kallend worked in various hospital departments in the UK, predominantly at the Royal Postgraduate Medical School Hammersmith Hospital, London, where his final post was Research Fellow in the Department of Surgery. In 1995 he joined the pharmaceutical industry. He initially worked as an International Clinical Research Physician on imaging studies for Schering AG in Berlin, predominantly in the area of magnetic resonance contrast media for abdominal and joint imaging. Following this he joined AstraZeneca, based in the UK, working mainly on the development of rosuvastatin from Phase II to Phase IV and the post-approval phase. He was also involved as an advisor to other cardiovascular programs and collaborations. From 2005 to 2012 he was the Global Clinical Leader and a Group Medical Director for dalcetrapib at Roche. In this role he was responsible for the clinical development plan during Phase II and Phase III. He was also an advisor for other lipid programmes and various due diligence procedures. His current role is Vice President and Global Medical Director for the early development lipid programs, Apo A-1 Milano and aPCSK9, at The Medicines Company. During these last 18 years he has been involved with many clinical studies in the cardiovascular area and several regulatory approvals.
|
|
|
